The partnership addresses one of the most persistent friction points in hospital pharmacy RFID adoption: the manual tagging of individual medication vials. Under the current model, pharmacy staff must apply RFID labels to each item after delivery, a time-consuming process that introduces the potential for human error and limits the scalability of RFID-based inventory systems. With SmartDose, RFID labels are applied during the manufacturing process itself, using GS1 encoding strategies to ensure each tag carries standardised identification data.

What sets SmartDose apart from previous source-tagging efforts is its automated readback verification step. Every vial undergoes a machine-driven check before release to confirm that the RFID tag is both accurate and readable. Bluesight describes this as a first for source-tagged medications, and it represents a significant quality assurance milestone for pharmaceutical RFID applications.

The market context underscores the timing of this move. Approximately one-third of U.S. hospitals currently utilise RFID technology for inventory management, patient safety, regulatory compliance, and reducing waste caused by medication expiration. As adoption continues to grow, the availability of pre-tagged medications removes a key barrier to entry for facilities that have been hesitant to commit to the manual overhead of in-house tagging programs.

Erin Pezant, Global Business Excellence Lead at Pfizer, highlighted the workflow benefits of the approach. By moving the tagging process upstream to the manufacturing stage, hospitals can eliminate manual steps from pharmacy operations while retaining the full advantages of RFID-enabled inventory tracking. This shift allows pharmacy teams to focus on patient care rather than logistics.

Kevin MacDonald, CEO and co-founder of Bluesight, pointed to the broader industry significance of the partnership. He noted that bringing together manufacturing expertise and hospital workflow knowledge creates a more scalable model for RFID adoption across the healthcare sector. The collaboration effectively lowers the technical and operational barriers that have slowed wider deployment of RFID in pharmaceutical supply chains.

Pfizer SmartDose medications are projected to become available for purchase in the second half of 2026. The rollout will target hospitals already using Bluesight’s KitCheck platform, with potential expansion as the source-tagging model proves its value in real-world pharmacy environments.

Bluesight currently serves more than 3,000 hospitals across the United States and Canada, providing AI-powered solutions for inventory management, procurement, and compliance. The addition of source-tagged medications to this ecosystem represents a natural evolution of the company’s mission to streamline pharmacy operations through technology.

Read more at https://bluesight.com/news/bluesight-and-pfizer-partner-to-provide-source-tagged-rfid-medications/

The post Bluesight and Pfizer to Provide Source-Tagged RFID Medications to Hospital Pharmacies first appeared on RFID News.